Preventable drug-related hospital admissions

OBJECTIVE: To estimate the prevalence of preventable drug-related hospital admissions (PDRAs) and to explore if selected study characteristics affect prevalence estimates. METHODS: Keyword search of MEDLINE (1966-December 1999), International Pharmaceutical Abstracts (1970-December 1999), and hand search. Two reviewers independently selected studies published in peer-reviewed journals and extracted crude prevalence estimates and study characteristics. Trials had to specifically address consequences of drug therapy requiring hospital admission and include a quantitative preventability assessment. Stratified analysis and meta-regression were used to explore the association between study characteristics and prevalence estimates. DATA SYNTHESIS: Fifteen studies reported a median PDRA prevalence of 4.3% (interquartile range [IQR] 3.1-9.5%). The median preventability rate of drug-related admissions was 59% (IQR 50-73%). No evidence of publication bias related to study size could be determined. Because the individual study results were highly heterogeneous (Cochran's Q = 176, df = 14; p < 0.001), no meta-analytic summary estimate was computed. Stratified analysis suggested an association between prevalence estimates and 3 study characteristics: exclusion of first admissions (readmission studies: average PDRA prevalence of 14.0 %, estimated prevalence OR = 3.7); mean age of admissions >70 (OR = 2.1); and inclusion of "indirect" drug-related morbidity, such as omission errors or therapeutic failure (OR = 1.9). There was little evidence of other associations with prevalence estimates, such as selection of specific hospital units, exclusion/inclusion of planned admissions, country, and specified methods of PDRA case ascertainment. CONCLUSIONS: Drug-related morbidity is a significant healthcare problem, and a great proportion is preventable. Study methods in prevalence reports vary and should be considered when interpreting findings or planning future research.

This article has been cited by other articles:

				P. J. Zed PharmD, R. B. Abu-Laban MD MHSc, R. M. Balen PharmD, P. S. Loewen PharmD, C. M. Hohl MD, J. R. Brubacher MD MSc, K. Wilbur PharmD, M. O. Wiens BSc(Pharm), L. J. Samoy BSc(Pharm), K. Lacaria BSc(Pharm), et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study Can. Med. Assoc. J., June 3, 2008; 178(12): 1563 - 1569. [Abstract] [Full Text] [PDF]

				E M A Witherington, O M Pirzada, and A J Avery Communication gaps and readmissions to hospital for patients aged 75 years and older: observational study Qual. Saf. Health Care, February 1, 2008; 17(1): 71 - 75. [Abstract] [Full Text] [PDF]

				M.F. Dallenbach, P.A. Bovier, and J. Desmeules Detecting drug interactions using personal digital assistants in an out-patient clinic QJM, November 1, 2007; 100(11): 691 - 697. [Abstract] [Full Text] [PDF]

				K. M. Cresswell, B. Fernando, B. McKinstry, and A. Sheikh Adverse drug events in the elderly Br. Med. Bull., September 1, 2007; 83(1): 259 - 274. [Abstract] [Full Text] [PDF]

				L. A. Thomsen, A. G Winterstein, B. Sondergaard, L. S. Haugbolle, and A. Melander Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care Ann. Pharmacother., September 1, 2007; 41(9): 1411 - 1426. [Abstract] [Full Text] [PDF]

				R. L. Howard and A. J. Avery Pharmacist-led medication reviews can reduce patient morbidity? Age Ageing, November 1, 2006; 35(6): 555 - 556. [Full Text] [PDF]

				E. A van Dijk, N. R. Drabbe, M. Kruijtbosch, and P. A. De Smet Drug Dosage Adjustments According to Renal Function at Hospital Discharge Ann. Pharmacother., July 1, 2006; 40(7): 1254 - 1260. [Abstract] [Full Text] [PDF]

				C J Morris, J A Cantrill, A J Avery, and R L Howard Preventing drug related morbidity: a process for facilitating changes in practice. Qual. Saf. Health Care, April 1, 2006; 15(2): 116 - 121. [Abstract] [Full Text] [PDF]

				A. G. Winterstein, A. G. Hartzema, T. E. Johns, J. M. De Leon, K. McDonald, Z. Henshaw, and R. Pannell Medication safety infrastructure in critical-access hospitals in Florida Am. J. Health Syst. Pharm., March 1, 2006; 63(5): 442 - 450. [Abstract] [Full Text] [PDF]

				S Royal, L Smeaton, A J Avery, B Hurwitz, and A Sheikh Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta-analysis Qual. Saf. Health Care, February 1, 2006; 15(1): 23 - 31. [Abstract] [Full Text] [PDF]

				M. Pirmohamed, S. James, S. Meakin, C. Green, A. K Scott, T. J Walley, K. Farrar, B K. Park, and A. M Breckenridge Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients BMJ, July 3, 2004; 329(7456): 15 - 19. [Abstract] [Full Text] [PDF]

				C J Morris, S Rodgers, V S Hammersley, A J Avery, and J A Cantrill Indicators for preventable drug related morbidity: application in primary care Qual. Saf. Health Care, June 1, 2004; 13(3): 181 - 185. [Abstract] [Full Text] [PDF]

				K. K Viktil, H. S Blix, A. Reikvam, T. A Moger, B. J Hjemaas, E. K Walseth, T. F Vraalsen, P. Pretsch, and F. Jorgensen Comparison of Drug-Related Problems in Different Patient Groups Ann. Pharmacother., June 1, 2004; 38(6): 942 - 948. [Abstract] [Full Text] [PDF]

				P. S Flanagan, N. J MacKinnon, S. K Bowles, and S. A Kirkland Validation of Four Clinical Indicators of Preventable Drug-Related Morbidity Ann. Pharmacother., January 1, 2004; 38(1): 20 - 24. [Abstract] [Full Text] [PDF]

				N Barber, M Rawlins, and B Dean Franklin Reducing prescribing error: competence, control, and culture Qual. Saf. Health Care, December 1, 2003; 12(90001): i29 - 32. [Abstract] [Full Text] [PDF]

				R L Howard, A J Avery, P D Howard, and M Partridge Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study Qual. Saf. Health Care, August 1, 2003; 12(4): 280 - 285. [Abstract] [Full Text] [PDF]